Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia

Al-Ali, Luma; Al-Ani, Raad J.; Saleh, Maysaa M.; Hammad, Alaa M.; Abuarqoub, Duaa A.; Abu-Irmaileh, Bashaer; Naser, Abdallah Y.; Najdawi, Manal M.; Abbas, Manal M.; Alyoussef Alkrad, Jamal

doi:10.1016/j.jsps.2023.101931

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A clinical study with CML patients receiving imatinib plus calcitriol showed a stabilization of the vitamin D levels, albeit without visible anticancer effects compared with imatinib alone [ 211 ] . A new preclinical study using the more active calcitriol analog inecalcitol synergistically enhanced the anticancer activities of imatinib and dasatinib against CML cells in vitro and might become a more suitable combination partner for these kinase inhibitors in future clinical trials for CML [ 212 ] .…”

Section: Myb Proteins and Cancer Drug Resistancementioning

confidence: 99%

Emerging role of MYB transcription factors in cancer drug resistance

Biersack,

Höpfner

2024

Cancer Drug Resist

View full text Add to dashboard Cite

Decades ago, the viral myeloblastosis oncogene v -myb was identified as a gene responsible for the development of avian leukemia. However, the relevance of MYB proteins for human cancer diseases, in particular for solid tumors, remained basically unrecognized for a very long time. The human family of MYB transcription factors comprises MYB (c-MYB), MYBL2 (b-MYB), and MYBL1 (a-MYB), which are overexpressed in several cancers and are associated with cancer progression and resistance to anticancer drugs. In addition to overexpression, the presence of activated MYB-fusion proteins as tumor drivers was described in certain cancers. The identification of anticancer drug resistance mediated by MYB proteins and their underlying mechanisms are of great importance in understanding failures of current therapies and establishing new and more efficient therapy regimens. In addition, new drug candidates targeting MYB transcription factor activity and signaling have emerged as a promising class of potential anticancer therapeutics that could tackle MYB-dependent drug-resistant cancers in a more selective way. This review describes the correlation of MYB transcription factors with the formation and persistence of cancer resistance to various approved and investigational anticancer drugs.

show abstract

Section: Myb Proteins and Cancer Drug Resistancementioning

confidence: 99%